The aging population is becoming an increasing socio-economical issue that needs to be addressed in order to sustain that demographic shift. It is therefore important to diagnose and treat as early as possible in order to live a healthy aging. Perceiv is a precision medicine company providing AI-based actionable biomarkers for the early detection of CNS diseases. We currently provide highly precise biomarkers of the progression to Alzheimer's dementia at a prodromal stage based on imaging.
Personalize treatment using individual characteristics of your patients.
Outcome prediction based on clinical data.
Reduce clinical trial cost using precision enrollment of patients.
Identification of preclinical population at high risk of future complications.
Population enrichment of clinical trials, using MRI (magnetic resonance imaging).
CEO & Founder. Dr. Dansereau has 8 years of experience doing machine learning research applied to neuroimaging and medical data. Ph.D. in Computer Science from University of Montreal. Master in Biomedical Engineering from McGill University. Bachelor degree in Electrical Engineering.
Scientific director of the functional imaging unit. Researcher at the CRIUGM, Computer Science and operations research, University of Montreal. Co-lead of the biomarker team of the Canadian Consortium on Neurodegeneration in Aging (CCNA).
Director of the Alzheimer’s Disease Research Unit at McGill University, Montreal, Canada. Professor of Neurology & Neurosurgery, Psychiatry and Medicine at McGill University, Montreal, Canada. Member, Douglas Mental Health University Institute’s Research Center. Membre Associé, Institut Universitaire de Gériatrie, Université de Montréal.
Deep learning, and statistical data analysis. Previously worked at Intel, Cisco and various startups. Masters in Electrical Engineering in the fields of deep learning and medical imaging from McGill University. Double B.Sc. in Electrical Engineering and Physics. .